MK-677

MK-677 acts as a selective agonist of the growth hormone secretagogue receptor (GHSR-1a), mimicking the action of endogenous ghrelin. By binding to this receptor, primarily in the pituitary gland and hypothalamus, it triggers a signaling cascade that stimulates the pulsatile release of growth hormone (GH).

• GHSR-1a activation: Binds with high affinity to the receptor, inducing a conformational change that activates the phospholipase C pathway and intracellular calcium mobilization.
• GH secretion: Receptor activation in somatotroph cells of the anterior pituitary promotes GH release into the bloodstream.
• IGF-1 increase: Circulating GH stimulates hepatic production of IGF-1, which mediates many anabolic and growth effects.
• Orexigenic effect: At the hypothalamic level, GHSR activation stimulates appetite, similar to ghrelin.

• Growth hormone deficiency: Investigated as an oral alternative to injectable GH therapy in children and adults with GH deficiency.
• Sarcopenia and frailty: Studied to improve muscle mass and strength in elderly individuals with age-related muscle loss.
• Osteoporosis: Evaluated for its potential to increase bone mineral density and reduce fracture risk.
• Fracture recovery: Investigated to accelerate bone healing in patients with hip fractures or other injuries.
• Sleep improvement: Observed to increase slow-wave sleep (deep sleep) duration in clinical studies.

The effects of MK-677 include a significant increase in serum GH and IGF-1 levels, which can translate into increased lean muscle mass, improved bone density, and reduced body fat. Improved sleep quality, particularly slow-wave sleep, has also been reported. However, the most common adverse effects are increased appetite (which can lead to weight gain), fluid retention (peripheral edema), joint pain, and fatigue. Long-term, there is concern about the development of insulin resistance and hyperglycemia, due to GH-induced suppression of insulin sensitivity.

MK-677 is not approved by the FDA or EMA for clinical use; it is only used in research. Unsupervised use carries significant risks. Contraindications include uncontrolled diabetes mellitus, history of cancer (especially GH/IGF-1 sensitive tumors), congestive heart failure, intracranial hypertension, and pregnancy. The most serious adverse effects are hyperglycemia and insulin resistance, which may be irreversible. It can also cause elevated liver enzymes, muscle pain, and peripheral neuropathy. Regular monitoring of blood glucose, IGF-1 levels, and liver function is recommended during use. It should not be combined with other GH secretagogues or insulin without medical supervision.

MK-677 has not been approved by any major regulatory agency (FDA, EMA, etc.) for clinical use in humans. It is currently classified as a research compound and is not available as a prescription medication. Its use is restricted to clinical trials and laboratory studies. In some countries, it may be regulated as a controlled substance or sold as a research supplement, but it is not intended for human consumption without medical supervision.

In clinical studies, the typical dose of MK-677 has been 10 to 25 mg per day, administered orally, usually as a single daily dose. Higher doses (up to 50 mg/day) have been used in some studies but with a higher incidence of adverse effects. Treatment duration in trials has ranged from weeks to several months. There is no established standard dose for unsupervised use.

MK-677 should be stored in a cool, dry place, protected from direct light and moisture. The recommended storage temperature is between 15-25°C (59-77°F). Do not freeze. Keep out of reach of children. Once reconstituted (if supplied as a powder), it should be used within a short period according to the manufacturer's instructions.